Clinical trials: First Line WT KRAS mCRC
First Line WT KRAS mCRC
PREMIUM, Observational Study
PREMIUM is an observational pharmaco-epidemiologic, transversal, multi-centric, prospective cohort study and with independent investigators.
- Trial name
- NCT01756625
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Dr.Laurent Mineur
Metastatic Colorectal Cancer
Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours
The purpose of the study is to evaluate the efficacy and safety of the combination of mFOLFOX-6 plus cetuximab for 8 cycles followed by mFOLFOX-6 plus cetuximab or single agent (s/a) cetuximab as maintenance therapy in patients…
- Trial name
- MACRO-2 (NCT01161316)
- Testing
- mFOLFOX-6 + cetuximab until disease progression or early withdrawal., 8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
- Where
- Spain
- Volunteers
- 194 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Metastatic Colorectal Cancer
Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR
The study will shed additional light on the impact of Vectibix® under the current, standard clinical conditions of mCRC treatment in Greece.
- Trial name
- VISION (NCT02322736)
- Where
- 20 sites in Greece
- Volunteers
- 218 people
- Sponsor
- Amgen